Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Laboratory consumables and reagents / Process-development and scale-up purification consumables (columns, resins, single-use assemblies)

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Process-development and scale-up purification consumables (columns, resins, single-use assemblies)

Chromatography columns and resins, single-use bags, filters, liners, fittings and process-scale plasticware bought by pharmaceutical and biotechnology process-development teams and by CDMO technology-transfer groups to develop, characterise and hand over manufacturing processes. Segmented by buyer organisation type (pharma/biotech process development and CDMO tech transfer) and the job of converting a discovery molecule into a transferable, scalable purification process. Excludes discovery assay work (niche 1), routine contract QC (niche 3), academic research (niche 4) and clinical sample logistics (niche 5).

Market size
$10.2B
$10.2B ($8.2B–$12.2B) · 2026 · Bottom-up
Growth
+8.0%
$15.0B by 2031
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
5 sources · Bottom-up
Level
Niche
Segmented by
Customer type
Buyers
Process development and MSAT teams in pharmaceutical and biotechnology companies; technology-transfer and process-development engineers at CDMOs
Buying centre
Director/lead of downstream process development, supported by bioprocess engineer and MSAT lead; commercial decision sits with technical procurement or supply-chain category manager under a multi-year supply agreement, often with quality assurance sign-off
Buying triggers
  • IND-enabling or clinical-supply campaign that forces a purification process to be locked and scaled
  • New molecule or new modality (e.g. antibody, oligo, cell and gene therapy) entering development
  • Technology transfer of a process to a CDMO or between internal sites
  • Post-approval or late-stage campaign requiring process robustness work and column lifetime extension
Pains
  • Column and resin supply lead times of many weeks that sit on the critical path to clinical supply
  • Specification lock-in: changing resin or column supplier requires re-validation and regulatory risk assessment
  • Inconsistent single-use component quality causing yield loss and batch rejection
  • Fragmented demand across development, MSAT and manufacturing with poor visibility of true pipeline demand
Scores (1–5)
Pain intensity—
Purchasing power—
Reachability5
Growth—

How this was sized

$10.2B ($8.2B–$12.2B) · 2026 · Bottom-up

Parent pool 2026 USD 60.4B (Emergen tools & reagents 2026 USD 109.77B [3] x 55% consumables-and-reagents share assumption; cross-check GVR 2026 USD 202.6B [1] x 30% = USD 60.8B; parent range USD 48-72B). Niche = parent x 17% assumed process-development and purification consumables share = USD 10.3B, rounded to USD 10.2B; range USD 8.2-12.2B (parent range x 17%). Forecast: 10.2 x 1.08^5 = USD 15.0B by 2031; CAGR set above the 6.0-6.9% tools-market CAGRs [2]/[3] to reflect biologics pipeline intensity, but below the 10.2% tools CAGR [1]/[7] because this is a consumables-led, capacity-constrained category.

Alongside it in Laboratory consumables and reagents

// Sell into Process-development and scale-up purification consumables (columns, resins, single-use assemblies)

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.